Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 1.00 |
| ▸ | UBE2M | P61081 | 3/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12004771 | 1.00 | GHSR (1.00) | GHSRUBE2MDCUN1D1SLC6A2SLC6A4 | |
| SCHEMBL12004577 | 1.00 | GHSR (1.00) | GHSRUBE2MDCUN1D1SLC6A2SLC6A4 | |
| SCHEMBL12004894 | 0.93 | GHSR (0.86) | GHSRUBE2MDCUN1D1SLC6A2SLC6A4 | |
| SCHEMBL12005497 | 0.91 | GHSR (0.83) | GHSRUBE2MDCUN1D1CCR5HTR2A | |
| SCHEMBL12004962 | 0.90 | GHSR (0.82) | GHSRUBE2MDCUN1D1 | |
| SCHEMBL12004807 | 0.88 | GHSR (0.78) | GHSRUBE2MDCUN1D1SLC6A2SLC6A4 | |
| SCHEMBL12004611 | 0.88 | GHSR (0.78) | GHSRUBE2MDCUN1D1SLC6A2SLC6A4 | |
| SCHEMBL12004609 | 0.88 | GHSR (0.78) | GHSRUBE2MDCUN1D1SLC6A2SLC6A4 | |
| SCHEMBL12006057 | 0.87 | GHSR (0.78) | GHSRUBE2MDCUN1D1SLC6A2SLC6A3 | |
| SCHEMBL12075513 | 0.87 | GHSR (0.78) | GHSRUBE2MDCUN1D1CCR5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | claimed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | claimed |
| EP-2678017-B1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-04-05 | — | — | EP | claimed |
| US-20140121210-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2014-05-01 | — | — | US | claimed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | claimed |
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | US | claimed |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA | 2019-09-10 | — | — | US | disclosed |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA | 2019-09-10 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | disclosed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | disclosed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | US | disclosed |
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | US | disclosed |
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | US | disclosed |
| WO-2012113103-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE S.A. (CH) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116176-A2 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | GHSR 3/4885UBE2M 1023/4885DCUN1D1 4727/4885 |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | UTS2R, GPR119, GHSR | GHSR 3/4885UBE2M 1023/4885DCUN1D1 4727/4885 |
| US-20140121210-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | GHSR 3/4885UBE2M 1023/4885DCUN1D1 4727/4885 |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | GHSR 3/4885UBE2M 1023/4885DCUN1D1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.